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Abstract: Choroidal neovascularization (CNV) secondary to age-related macular degeneration 
(AMD) is now the leading cause of blindness and severe vision loss among people over the age 
of 40 in the Western world. Its prevalence is certain to increase substantially as the population 
ages. Treatments currently available for the disease include laser photocoagulation, verteporﬁ  n 
photodynamic therapy, and intravitreal injections of corticosteroids and anti-angiogenic agents. 
Many studies have reported the beneﬁ  ts of each of these treatments, although none is without 
its risks. No intervention actually cures AMD, nor the neovascularization associated with it. 
However, its symptoms are treated with varying degrees of success. Some treatments stabilize 
or arrest the progress of the disease. Others have been shown to reverse some of the damage 
that has already been done. These treatments can even lead to visual improvement. This paper 
will review the major classes of drugs and therapies designed to treat this condition.
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Introduction
Age-related macular degeneration (AMD) was ﬁ  rst described in the medical literature 
well over a century ago1,2 and yet it was not until the 1970s that an intervention was 
proposed. It took another 30 years for treatments to be developed that would actually 
arrest the progress of the disease, and in some cases, restore a degree of lost visual 
acuity (VA). This contrasts with other ocular diseases such as glaucoma, which was 
described in detail by Albrecht von Graefe more than 150 years ago. He introduced 
the iridectomy as a means of lowering intraocular pressure, thus providing the ﬁ  rst 
effective treatment for closed angle glaucoma. It was not until 1980 that macular 
degeneration was reported to be a signiﬁ  cant cause of blindness in the United States.3 
Since then, many studies have expanded upon the risks associated with new blood 
vessel growth in the aging retina, and have shown just how serious and widespread a 
public health issue AMD represents.
A 2004 analysis4 reported that among Americans over the age of 40, AMD and/or 
geographic atrophy were present in at least one eye in 1.47% of the population, and 
that 1.75 million individuals have AMD. Among women over the age of 85, 15% have 
AMD. Approximately 7 million Americans have drusen measuring 125 microns. 
The presence of large drusen is a known risk factor for the disease, and suggests that 
these people could face a substantial risk of going blind. Given the aging population, 
it is forecast that there may be a 50% increase in the incidence of AMD before the 
year 2020. In another study,5 AMD was reported to account for 54% of all current 
cases of blindness among the Caucasian population in the United States. The study 
predicted that as a result of the rising prevalence of AMD, the number of blind people 
in the US could increase by as much as 70% by 2020. Meanwhile, a multi-country 
European study6 has reported that 3.3% of the population over age 65 has grade 4 Clinical Ophthalmology 2009:3 176
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AMD (ARM International Classiﬁ  cation System7), and 2.3% 
have choroidal neovascularization (CNV).
Laser photocoagulation
The earliest treatment for AMD was pan-retinal photocoagu-
lation (PRP). This was originally used for the treatment of 
diabetic retinopathies.8 Key studies in the 1980s9–11 reported 
that patients with AMD, known at that time as senile macular 
degeneration, who were at risk of developing CNV were less 
likely to experience severe vision loss if they were treated 
with laser thermotherapy rather than having no treatment at 
all. In 1976, the Macular Photocoagulation Study (MPS)10 
demonstrated a ﬁ  ve-year event-free rate of 36% (an event was 
deﬁ  ned as the loss of six or more lines on the Early Treatment 
Diabetic Retinopathy Study [ETDRS] chart from baseline) 
for untreated patients, compared with a 54% event-free rate 
for patients who underwent argon laser photocoagulation. 
Despite the promise that laser photocoagulation offered for 
some patients, the beneﬁ  ts were inconsistent, the risks were 
substantial, and recurrences were frequent. In 1990, the MPS 
group also showed12 that when patients were treated with 
krypton red laser photocoagulation, one-third would have 
persistent neovascularization within six weeks of the initial 
treatment, and 47% would have recurrent neovascularization 
within ﬁ  ve years. Both persistent and recurrent disease were 
associated with severe vision loss.
In the Moorsﬁ  eld study11 in Britain, in 1982, there was 
a numerical superiority in terms of the number of patients 
whose visual acuity improved when they were treated with 
argon laser. However, the difference between treated and 
untreated groups was only signiﬁ  cant at the p = 0.05 level 
among those who had the worst visual acuity (VA) at base-
line. The differences were not signiﬁ  cant among patients 
who had better baseline VA (6/24 or 6/36).
There are other important limitations to laser photoco-
agulation. It destroys the overlying retina, and therefore can 
cause signiﬁ  cant and permanent loss of some vision. It can-
not be employed where there is subfoveal CNV leakage, and 
must be used not less than 200 microns outside the fovea. It 
is applicable only for lesions that can be clearly deﬁ  ned in 
the early phase of ﬂ  uorescein angiography, which rules out 
its use for occult neovascularization. In total, laser photoco-
agulation may only be appropriate for approximately 15% 
of potential patients with CNV.13
Intravitreal corticosteroids
Numerous investigators over the years have reported that a 
signiﬁ  cant factor in the pathogenesis of AMD is inﬂ  ammation. 
It has therefore been suggested that corticosteroids could play a 
role in treating or preventing the inﬂ  ammatory process. There is 
good rationale for the use of steroids in treating CNV. Besides 
reducing inﬂ  ammation, steroids block the up-regulation of vas-
cular endothelial growth factor (VEGF), which is produced and 
released by all inﬂ  ammatory cells.14 Corticosteroids are thought 
to reduce vascular leakage because they close up the gaps that 
form between endothelial cells in the capillary walls. They also 
limit ﬁ  brosis, which reduces scarring in the retina.
The corticosteroid triamcinolone acetonide, administered 
intravitreally (IVTA) was proposed as a treatment because 
prior studies had shown that it could inhibit ﬁ  brovascular 
proliferations in rats with laser-induced CNV.15 Other studies 
reported the same effect in primates, with safety and toler-
ability studies showing that it was well-tolerated in both 
rabbits and primates.16–18
In human trials, IVTA was shown to stabilize the prog-
ress of AMD as seen on fundus photography and ﬂ  uorescein 
angiography, and/or to improve visual acuity.19–21 Those 
studies used 4 mg doses of triamcinolone; one study22 
however, investigated the use of repeat injections of 25 mg. 
No unexpected adverse events were reported as a result of 
the higher dose, although the improvements in visual acuity 
were not signiﬁ  cantly better than those seen when the lower 
dose (4 mg) was used. In any case, not all triamcinolone 
studies produced encouraging results. Gillies and colleagues23 
followed patients who received a single injection of 4 mg 
IVTA vs patients who received a placebo for a minimum 
period of one year. The study revealed a signiﬁ  cant difference 
in the size of the neovascular membrane favoring patients 
who received the steroid at the end of three months, but this 
difference disappeared by the end of the one-year follow-up. 
Moreover, 35% of both treated and untreated patients expe-
rienced a loss of 30 ETDRS letters. Besides showing 
little real beneﬁ  t for triamcinolone compared with placebo, 
the study reported that 41% of patients receiving IVTA 
had signiﬁ  cant increases in intraocular pressure compared 
with 4% of patients in the control group. Similar increases 
in intraocular pressure (IOP) were also seen in subsequent 
trials,24,25 and have come to represent a substantial risk for 
patients who have, or are at risk of developing open angle 
glaucoma.
A second steroid, dexamethasone, has a more or less 
similar anti-angiogenic effect to triamcinolone. However, 
it is shorter-acting, and is administered in solution form, 
rather than as a suspension. Therefore it is cleared from the 
vitreous faster than triamcinolone. Dexamethasone does not 
reduce the trabecular drain as severely as triamcinolone, Clinical Ophthalmology 2009:3 177
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so it is not associated with the spikes in IOP that are seen 
with triamcinolone use.
Verteporﬁ  n photodynamic therapy
Photodynamic therapy with verteporﬁ  n (V-PDT) entails 
a two-part process with the photosensitizer (verteporﬁ  n) 
injected intravenously ﬁ  rst. This is followed by controlled 
exposure to blue laser light, at 689 nM, 600 mW/cm2, 
50 J/cm2, for 83 seconds. Neovascularization is eradicated 
when the verteporﬁ  n, which accumulates in the choroidal 
vessels, is activated by the laser light, and generates reactive 
oxygen species. These attach to localized endothelial cells, 
causing platelet binding and aggregation. This blocks further 
blood ﬂ  ow through the vessels, and in fairly quick order, 
atrophy of the neovascularization follows. Blood vessels that 
have been eradicated in this way do not grow back, although 
other vessels will still be formed within the subretinal space 
due to continued expression of VEGF.
V-PDT gained rapid acceptance following its release in 
North America and Europe in 1999. Initially it was approved 
for the treatment of subfoveal, predominantly classic AMD 
lesions of all sizes. Indications have expanded to include 
occult with no classic lesions, certain minimally classic 
lesions, lesions of 4 MPS disk areas (DA), and CNV sec-
ondary to pathological myopia.
The ﬁ  rst trial to report the beneﬁ  ts of V-PDT was the 
Treatment of Age-related Macular Degeneration with Pho-
todynamic Therapy (TAP) study.26 The protocol used in this 
study continues to inform the use of this agent.
The TAP study comprised two separate randomized 
double-masked placebo-controlled clinical trials involving 
a total of 609 patients who had predominantly classic AMD 
with CNV. At 12 months follow-up, 61% of patients in the 
treatment arm lost 15 letters vs 46% in the placebo arm. At 
24 months follow-up, 53% and 38% of the two groups respec-
tively lost 15 letters. More than twice as many patients in 
the V-PDT group had a complete absence of CNV leakage 
compared with the placebo group. These subjects have now 
been followed out to more than ﬁ  ve years, during which they 
received an average of 7.6 treatments. The most recently 
published paper27 reported minimal changes in visual acuity 
between months 24 and 60. Approximately 21% of patients 
lost 1 to 3 lines at two years, and the same percentage was 
followed out to year 5. Of the patients with predominantly 
classic lesions, 41% had a loss of 6 lines (30 letters) or less at 
month 24, compared with 55% at month 60. The authors cau-
tion that there were many factors, including a substantial rate 
of discontinuation, which could have caused these numbers 
to appear artiﬁ  cially low. Also, since there was no control 
group in years 3 to 5, it is not known whether subjects who 
were treated did any better than untreated subjects would 
have done between months 24 and 60.
A study of 339 patients with occult with no classic neo-
vascularization28 reported that after two years follow-up, 54% 
and 30% of V-PDT treated patients lost 15 letters and 30 
letters of VA respectively, compared with 67% and 47% of 
patients who received a sham treatment. A sub-group analysis 
found that patients were more likely to demonstrate stable 
vision, or even a visual gain at 24 months follow-up when 
they had worse vision (65 letters or 20/200) or lesions 
of 4 disk areas diameter at baseline.
A further subset analysis revealed an interesting and 
highly useful fact about V-PDT treatments and patient 
response rates.29 While the above trials looked at all lesion 
characteristics, multiple linear regression modeling revealed 
a significant correlation between treatment outcomes 
and lesion size for minimally classic and occult with no 
classic lesions, but not for predominantly classic lesions. 
Smaller lesions were associated with less loss of visual acu-
ity, regardless of lesion composition. Thus, lesion size at 
baseline (4.0 DA, whether minimally classic, or occult with 
no classic) was determined to be more predictive of outcome 
than either lesion composition or baseline visual acuity.
The ﬁ  rst randomly-controlled double-masked study 
investigating the safety and efﬁ  cacy of V-PDT in patients 
with minimally classic CNV30 produced mixed results. 
This study involved 117 patients randomized to either the 
V-PDT at a reduced ﬂ  uence rate (RF, ie, 300 mW/cm2 for 
83 seconds at 25 J/cm2), V-PDT at the standard ﬂ  uence (SF, 
ie, 600 mW/cm2 for 83 seconds, at 50 J/cm2) or placebo. 
Patients had lesions of 6 DA. While the difference in 
the mean change in VA from baseline favored the RF arm 
over the SF arm at 12 and 24 months, these differences 
were minor (usually less than one line) and not particularly 
robust compared with placebo. However, signiﬁ  cantly more 
patients (28%) in the placebo arm progressed to predomi-
nantly classic lesions during the follow-up period compared 
with patients in the V-PDT groups (5% and 3% for RF and 
SF groups respectively). Because of these inconclusive 
results, the Royal College of Ophthalmologists in Britain has 
recommended that V-PDT not be used for minimally classic 
lesions. In the United States, it has been recommended in 
cases where there are minimally classic lesions with signs 
of recent disease progression.
Although numerous studies continue to be conducted with 
V-PDT, these above-noted trials paved the way for much Clinical Ophthalmology 2009:3 178
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greater use of this intervention, and still represent the most 
important evidence-based research to justify the use of this 
procedure for treating AMD with CNV.
As a result of these studies, V-PDT has been shown to 
be safe and effective for treating a range of lesion types, 
including predominantly classic lesions, CNV secondary to 
pathological myopia, and occult with no classic subfoveal 
lesions. A combined analysis29 of the two main V-PDT studies 
referenced here26,27 showed that V-PDT can be used to treat 
lesions of 4 DA. And ﬁ  nally, subfoveal minimally classic 
lesions which meet additional criteria may, in some cases, 
be managed successfully with V-PDT.
Anti-angiogenic factors
As the human eye ages, choroidal vascular atrophy and a 
number of other factors lead to oxidative stress and hypoxia, 
which result in local inﬂ  ammation in the sub-retinal layers. This 
inﬂ  ammation causes an up-regulation of VEGF, a protein which 
among other pro-angiogenic factors stimulates the formation 
of new blood vessels.31 VEGF also upregulates the production 
and release of matrix metallo-proteinases (MMP) 2 and 9. This 
degrades the extracellular matrix and leads to endothelial leak-
age, as well as vascular endothelial cell migration and prolifera-
tion. CNV then penetrates Bruch’s membrane and the retinal 
pigment epithelium (RPE), leading to vision loss.
At this time, three anti-angiogenic drugs (VEGF-inhibitors) 
are available to treat neovascularization. The ﬁ  rst to enter the 
marketplace was pegaptanib sodium, a 28-base anti-VEGF 
aptamer, which antagonizes the speciﬁ  c amino acid isoform 
165 when administered intravitreally, and blocks new blood 
vessel growth.
The pivotal study with pegaptanib sodium was the multi-
center VEGF Inhibition Study in Ocular Neovascularization 
(VISION trial)32 which enrolled 1190 patients. They were 
treated with either 0.3 mg, 1.0 mg, or 3.0 mg of pegaptanib 
every six weeks (n = 892), or with a sham injection. The study 
included all lesion subtypes: predominantly classic, mini-
mally classic, and occult with no classic CNV. At 54 weeks 
follow-up, patients treated with pegaptanib showed signiﬁ  cant 
clinical beneﬁ  ts compared with patients in the placebo group. 
Overall, 70% of patients treated with pegaptanib sodium expe-
rienced a vision loss of 15 ETDRS letters, compared with 
55% of patients who received a sham injection (p  0.001). 
No difference in outcomes was detected among patients who 
received either 1.0 mg or 3.0 mg of the drug compared with 
0.3 mg. The treatment effect was consistent regardless of 
baseline visual acuity, lesion sub-type or whether the lesions 
were 4 or 4 DA.
The introduction of pegaptanib was followed closely by 
the emergence of two other more effective VEGF inhibitors: 
ranibizumab and bevacizumab. The use of bevacizumab as 
an ocular anti-angiogeneic is controversial, especially for the 
company that developed the drug (Genentech Inc., South San 
Francisco CA, USA). It was originally intended for use in the 
treatment of colorectal cancer, namely to inhibit metastatic 
angiogenesis. Ranibizumab, also developed by Genentech, 
is signiﬁ  cantly more costly, but any greater efﬁ  cacy remains 
to be proven. Bevacizumab has not been approved for ocular 
use in any country by any licensing authorities; nonetheless, 
it is widely used off-label to treat AMD and other condi-
tions of the eye. Bevacizumab is a full-length, humanized 
monoclonal antibody (149 Kd molecular weight) which, 
unlike pegaptanib, is directed against all biologically active 
isoforms of VEGF-A. Both drugs are derived from the same 
mouse antibody against VEGF; ranibizumab is thought to 
have a greater binding afﬁ  nity for VEGF owing to its smaller 
molecular weight (48 Kd).
Published studies involving patients treated with 1.25 mg 
bevacizumab33,34 injections spaced one month apart, have 
demonstrated signiﬁ  cant improvements in retinal thickness 
in as little as one week after the ﬁ  rst injection, and signiﬁ  cant 
improvements in VA, which are deﬁ  ned by a halving of the 
visual angle have also been observed at three months. Such 
improvements appear to be sustained over several months.
The typical dose of bevacizumab is 1.25 mg. A small 
study35 that included intravitreal injections of 2.5 mg enrolled 
17 patients who either were not candidates for, or had failed 
V-PDT therapy. Signiﬁ  cant improvements in VA (p  0.001) 
from baseline at four and eight weeks could be observed. 
No appreciable improvement in VA was noted beyond that. 
In the absence of a comparator group, however, it remains 
impossible to say whether there was any beneﬁ  t to treating 
these patients with the higher dose.
No signiﬁ  cant adverse events or other safety issues have 
been identiﬁ  ed in any of the studies with bevacizumab. This 
is an important consideration given that when the drug is 
used in the oncology setting, the side effects include delayed 
wound healing, increased hypertension, and gastric bleeding 
and perforations.
A third monoclonal antibody against VEGF, and the 
second to be approved for the treatment of AMD-associated 
CNV, is ranibizumab. Like bevacizumab, ranibizumab binds 
all isoforms of VEGF-A. Both are derived from the same 
mouse antibody against VEGF, but while bevacizumab is 
the full-length antibody, ranibizumab is only a Fab frag-
ment of it.Clinical Ophthalmology 2009:3 179
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The main published study36 with ranibizumab (Minimally 
Classic/Occult Trial Age-Related Macular Degeneration, 
or MARINA) was a two-year, phase III trial designed to 
evaluate monthly injections in 716 patients with mini-
mally classic or occult with no classic lesions. All of these 
patients had recurrent disease. They were randomized 1:1:1 
to receive either sham injections (n = 238), or injections 
of ranibizumab at 0.3 mg (n = 238) or 0.5 mg (n = 240). 
The 12-month primary endpoint analysis revealed that at 
least 94% of patients in both arms receiving ranibizumab 
lost fewer than 15 letters, compared with 62% of patients 
in the sham treatment arm. These results were also carried 
out to 24 months. A gain in VA of at least 15 letters was 
observed in 25% of patients in the 0.3 mg ranibizumab arm, 
and 34% of patients in the 0.5 mg ranibizumab arm. The 
gains in visual acuity occurred regardless of lesion type or 
size, or baseline VA, and were evident within seven days 
of the ﬁ  rst injection.
The next study37 (Anti-VEGF Antibody for the Treatment 
of Predominantly Classic Choroidal Neovascularization in 
Age-Related Macular Degeneration; ANCHOR) compared 
the same two dosage strengths of ranibizumab against V-PDT 
in 423 patients who were followed out to 12 months. At that 
point, patients in the ranibizumab 0.5 mg arm gained, on 
average, 11.3 letters, while patients in the V-PDT arm lost, 
on average, 9.5 letters, for an overall difference in treatment 
effect of 20.8 ETDRS letters. The outcomes were more or 
less similar at month 24. In addition, approximately 95% of 
patients in both ranibizumab arms lost fewer than 15 letters, 
while 35% and 40% of patients in the 0.3 mg and 0.5 mg 
arms respectively gained more than 15 letters compared 
with patients who were treated with V-PDT. Interestingly, a 
sub-group analysis38 reported that as lesion size increased, 
the beneﬁ  t of ranibizumab 0.5 mg became less signiﬁ  cant 
when compared with V-PDT.
In general, ranibizumab was well-tolerated. Adverse 
events that did occur were more frequent in patients receiving 
the higher 0.5 mg dose. The most frequent ocular adverse 
events included local injection site and ocular inﬂ  ammation, 
as well as spikes in intraocular pressure, which could be sig-
niﬁ  cant but appeared to be transient. Nonocular hemorrhage 
was seen more often in patients receiving ranibizumab com-
pared with the other two groups. Arteriothrombolic events, 
which include nonfatal myocardial infarction and/or stroke, 
and death from other vascular causes, were seen in 3.8% of 
patients receiving 0.3 mg of ranibizumab and 4.6% of those 
receiving the 0.5 mg dose. These rates did not differ from 
patients who received the sham injection. Rosenfeld and 
colleagues39 investigated several doses of ranibizumab and 
recommended 0.5 mg as the optimal dose.
An issue that has generated no small amount of contro-
versy, in both the medical literature and in the daily press, 
has to do with the cost of ranibizumab. Its price is listed40 
at US$1950 wholesale per dose. For a drug that requires 
monthly injections, this may represent a considerable bur-
den for many patients. Bevacizumab, which has the same 
mechanism of action, and only a slightly different molecular 
structure, is said to cost US$17–$50 per injection, but it is 
used off-label. Patients are therefore faced with the dilemma 
of being treated with a very expensive drug which has 
been approved for use in the United States and many other 
countries, but may require indeﬁ  nite monthly injections, or 
a similar drug that is much cheaper, but is not approved for 
ocular use. The National Eye Institute is now conducting, at 
its own expense, a head-to-head trial to determine whether 
there is a difference in efﬁ  cacy between these two drugs.
To help address the issue of dealing with the cost of 
monthly treatments, trials have been carried out to inves-
tigate different dosing regimens with ranibizumab.41,42 At 
ﬁ  rst glance, the rationale for ﬂ  exible dosing, or “as needed 
dosing” appears to make sense. Because VEGF inhibitors 
have a short half-life, their effects wear off fairly quickly. 
Regular injections of ranibizumab could therefore be needed 
indeﬁ  nitely. In the two main ranibizumab trials cited here36,37 
most of the beneﬁ  t occurred within the ﬁ  rst three months of 
treatment. The improvements in VA between months 3 and 
12 were modest at 1.8 and 1.5 letters for the two studies, 
respectively. Therefore, it was reasoned that patients might 
be able to achieve signiﬁ  cant gains in VA within the ﬁ  rst 
three months, and that additional treatments could be given 
on an “only as needed” basis.
In the Prospective Optical Coherence Tomography 
Imaging of Patients with Neovascular AMD Treated with 
intra-Ocular ranibizumab (PrONTO) trial41 40 patients 
received ranibizumab 0.5 mg at baseline, and then again at 
months 1 and 2. They did not receive additional treatments 
unless certain pre-speciﬁ  ed criteria were met. These criteria 
included a loss of 5 ETDRS letters, and/or an increase in 
macular thickness of at least 100 microns, continued subretinal 
ﬂ  uid detected by optical coherence tomography (OCT) after 
one month, new hemorrhage, and new neovascularization. An 
analysis of 37 patients produced encouraging data in terms 
of reduced retinal thickening, and improved VA, but for a 
number of reasons, these results cannot be generalized to 
clinical practice. First, this was a single center trial, involving 
only 40 patients. Also, patients in this study had all types Clinical Ophthalmology 2009:3 180
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of lesions, unlike subjects in either of the other studies.36,37 
Moreover, this was an open-label, unmasked study, in which 
patients had received prior therapies.
In a second study,42 (A Phase IIIb, Multicenter, Randomized, 
Double-Masked, Sham Injection-Controlled Study of the 
Efﬁ  cacy and Safety of Ranibizumab in Subjects with Subfoveal 
Choroidal Neovasularization with or without Classic CNV 
Secondary to Age-Related Macular Degeneration; PIER) 
patients received injections of ranibizumab 0.3 mg or 0.5 mg, 
or a sham, at baseline, and then again at months 1 and 2. Further 
injections were given at three-month intervals (ie, months 5, 
8, 11), for a total of six injections over 11 months. Initially, 
patients receiving the higher dose of 0.5 mg ranibizumab had 
a 4.3 letter gain in VA over the ﬁ  rst three months (ie, while 
monthly injections were being given), but this gain quickly 
deteriorated once quarterly dosing was commenced. At the 
end of 12 months, these patients had a mean decrease in VA 
of 0.2 letters from baseline. Along with the loss in VA, the 
patients also experienced renewed vascular leakage as seen 
on ﬂ  uorescein angiography, and increases in mean retinal 
thickness as seen on OCT. These data suggest that neither 
quarterly, nor “as needed” dosing of ranibizumab is useful in 
anything but the short term, and that monthly injections are 
likely needed to ensure any kind of viable treatment effect. 
Additionally, OCT ﬁ  ndings should be considered for the 
adjustment of the dosing regimen.
In general, few serious adverse events have been reported 
following ocular treatment with anti-VEGF drugs, with the 
exception of case reports of RPE tears following anti-VEGF 
administration. There is a wide variance in the incidence of 
these tears, ranging from less than one percent 43,44 to 17% 45, 
and because of the size of the studies, these numbers are 
relatively low. Nonetheless, these are important events and 
can result in signiﬁ  cant, permanent loss of vision.
Most cases of RPE tear occur in the presence of pigment 
epithelial detachment (PED) lesions, and it appears that ﬁ  bro-
vascular lesions are more susceptible to RPE tears than serous 
lesions. This suggests that either these patients have very fragile 
RPE structure, that they had a more severe form of CNV, or 
perhaps that they are somehow predisposed to weakened RPE, 
or already had pre-existing PED. Chiang and colleagues45 have 
reported that the risk of developing an RPE tear correlates 
directly with the diameter and height of the PED size, as well 
as with the presence of subretinal ﬂ  uid as seen on OCT.
Combination therapy
Each of the interventions discussed in this paper has its own 
particular strengths and limitations, but no single treatment 
offers a perfect solution or a cure for AMD-associated CNV. 
Augustin and colleagues have had some notable success 
by combining bevacizumab, V-PDT, and the steroid dexa-
methasone into a “triple therapy regimen” that attacks CNV 
through three different mechanisms. V-PDT eradicates exist-
ing neovascularization. Bevacizumab, the anti-angiogenic, 
prevents the growth of new blood vessels in the eye. And 
ﬁ  nally, besides being an anti-inﬂ  ammatory, the corticosteroid 
dexamethasone has anti-angiogenic properties and anti-
ﬁ  brotic and anti-permeability characteristics, which help 
preserve the integrity of the blood–retinal barrier.
In Augustin’s interventional case series,46 104 patients 
with all types of choroidal neovascularization were treated 
with V-PDT at a reduced light dose of 70 seconds, intravit-
real dexamethasone (800 μg), and bevacizumab (1.25 mg). 
The mean VA improved from 20/126 at baseline to 20/85 at 
40 weeks follow-up. This corresponds to an improvement of 
1.8 ETDRS lines or 8.9 letters. There was also a signiﬁ  cant 
decrease in retinal thickness, from 463.5 microns at baseline, 
to 281 microns at 40 weeks follow-up. This indicates that 
both functional and anatomical improvements were seen 
with this triple therapy regimen. These results have now 
been carried out to 70 weeks follow-up.
Customized therapies
Each of the treatments reported so far concentrates mainly 
on one aspect of AMD-associated CNV (for example laser 
photocoagulation on the newly grown vessels) and therefore 
has its strengths and its weaknesses. Augustin’s triple therapy 
regimen offers another attractive alternative for treatment, 
because it relies on three different mechanisms of action: 
eradicating existing CNV (vaso-occlusive), preventing new 
CNV (anti-angiogenic), and countering the inﬂ  ammatory 
process.
With that in mind, we herein see the great advantage of a 
therapy tailored to address not only the speciﬁ  c characteristics 
of a patient’s disease (ie, minimally classic or predominantly 
classic lesions), but the patient’s personal circumstances as 
well. Customized therapies should offer a more efﬁ  cacious 
intervention, a treatment that poses less of a burden for the 
patient personally or ﬁ  nancially, and one that is less of a 
burden for the caregivers and for the healthcare systems in 
general. There are many citations in the literature that deal 
with “individualized therapy”, but these are predominantly 
in diseases such as cancer, diabetes, psychiatric/emotional 
disorders, hypertension and HIV/AIDS. The only applica-
tion where one has spoken of customized therapy in the 
ophthalmology context has been certain studies that have Clinical Ophthalmology 2009:3 181
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investigated combination of ocular hypotensive drugs to 
lower IOP in glaucoma patients.
Ophthalmologists now have a good understanding of 
the pathophysiology and biochemistry behind CNV, but we 
must build upon this knowledge in order to develop such 
customized therapies. We already employ treatments with 
various doses of laser light and VEGF inhibitors, but at this 
time, we do not have an algorithm to inform us of which 
patient may respond best to a particular therapy, or whether 
a patient may respond better to more of one agent, and less 
of another. Even something as simple as delivering photody-
namic therapy and ranibizumab on the same day, rather than 
on two separate occasions, is being investigated.47 According 
to preliminary data, same-day administration may result in 
less endophthalmitis and uveitis compared with treatments 
delivered days apart. Reductions in lesion dimensions and 
central retinal thickness were also observed.48
Finding the elusive “customized treatment” is not the 
same as ﬁ  nding a new drug, although a long list of new drugs 
with novel mechanisms of action are being developed. These 
new interventions will act more “upstream” and will address 
the issue of oxidative stress, drusen formation, inﬂ  ammation, 
and other steps in the cascade that lead to new vessel growth 
and vision loss. Such pharmacologic approaches may focus 
on genetic factors such as the Y402H polymorphism which 
lead to an inappropriate inﬂ  ammatory response at the level 
of the complement system. Several complement cascade 
inhibitors are now under development. Other long-range 
pharmacologic interventions could include drugs to boost, or 
augment naturally occurring factors that antagonize angio-
genesis. These factors are known to include pigment-derived 
epithelial factor and endostatin.
Conclusion
During the past four decades there have been some highly 
encouraging and much needed improvements in the man-
agement of CNV secondary to AMD. Early treatments 
like laser photocoagulation prevented the rapid spread of 
CNV, but often led to some degree of permanent vision 
loss. V-PDT arrested the progress of the disease and even 
improved visual acuity for a small percentage of patients. 
Anti-angiogenic agents (VEGF inhibitors) now offer improve-
ments in visual acuity for at least one-third of patients. Apart 
from VEGF, many other anti-angiogenic factors exist and 
may be rewarding targets of future studies. Those studies 
should not only aim to identify additional important factors 
being involved in the pathogenesis of the disease entity but 
also investigate new treatment approaches.
Each of the developments discussed here has been built 
upon the strengths of its predecessors, continually improv-
ing the effective treatment of CNV secondary to AMD. 
These improvements will become even more signiﬁ  cant as 
the population ages and the prevalence of vision loss due to 
AMD becomes more widespread.
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